High Versus Lower Intensity Surveillance Following Resection of Retroperitoneal Sarcoma

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

584

Participants

Timeline

Start Date

November 30, 2024

Primary Completion Date

December 31, 2033

Study Completion Date

December 31, 2033

Conditions
Sarcoma,Soft TissueSarcoma Retroperitoneal
Interventions
DIAGNOSTIC_TEST

High-intensity radiological surveillance

The standard approach to surveillance imaging will be contrasted CT (IV and oral contrast) of the chest, abdomen and pelvis. All patients require radiological assessment of the chest, abdomen and pelvis at each surveillance round. Tolerance will be given in the protocol for selected patients where CT is not suitable to receive alternative imaging such as MRI or combination of MRI and CT. Uncontrasted CT imaging is permissible where renal toxicity or allergy from intravenous contrast is of concern. The use of plain radiography is not permitted as an alternative to CT imaging of the chest.

DIAGNOSTIC_TEST

Lower-intensity radiological surveillance

The standard approach to surveillance imaging will be contrasted CT (IV and oral contrast) of the chest, abdomen and pelvis. All patients require radiological assessment of the chest, abdomen and pelvis at each surveillance round. Tolerance will be given in the protocol for selected patients where CT is not suitable to receive alternative imaging such as MRI or combination of MRI and CT. Uncontrasted CT imaging is permissible where renal toxicity or allergy from intravenous contrast is of concern. The use of plain radiography is not permitted as an alternative to CT imaging of the chest.

Trial Locations (2)

20133

Fondazione IRCCS Istituto Nazionale dei Tumori, Milan

B15 2GW

University Hospitals Birmingham NHS Foundation Trust, Birmingham

All Listed Sponsors
collaborator

University of Birmingham

OTHER

collaborator

University Hospital Birmingham NHS Foundation Trust

OTHER

collaborator

Royal Marsden NHS Foundation Trust

OTHER

collaborator

University Hospital Padova

OTHER

collaborator

Campus Bio-Medico University

OTHER

collaborator

The Netherlands Cancer Institute

OTHER

collaborator

KU Leuven

OTHER

collaborator

Heidelberg University

OTHER

collaborator

Dana-Farber/Brigham and Women's Cancer Center

OTHER

collaborator

Emory University

OTHER

collaborator

Mayo Clinic

OTHER

collaborator

Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium

OTHER

collaborator

The Cleveland Clinic

OTHER

collaborator

M.D. Anderson Cancer Center

OTHER

collaborator

University of Southern California

OTHER

collaborator

Ohio State University

OTHER

collaborator

Ottawa Hospital Research Institute

OTHER

collaborator

McGill University

OTHER

collaborator

Peter MacCallum Cancer Centre, Australia

OTHER

collaborator

Royal Prince Alfred Hospital, Sydney, Australia

OTHER

lead

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

OTHER